Amitabh C Pandey1,2, Derek Jer3, Ruth S Kuo3, David H Yoo1, Antonio Christophy1,4, Rajeev C Mohan1,4, Ajay V Srivastava1,4, James Thomas Heywood1,4. 1. Division of Cardiology, Scripps Prebys Cardiovascular Institute, Scripps Clinic, La Jolla, California, USA. 2. Scripps Research Translational Institute, The Scripps Research Institute, La Jolla, California, USA. 3. Department of Pharmacy, Scripps Clinic, La Jolla, California, USA. 4. Section of Advanced Heart Failure and Mechanical Circulatory Support, Division of Cardiology, Scripps Prebys Cardiovascular Institute, Scripps Clinic, La Jolla, California, USA.
Abstract
BACKGROUND: Widespread use of angiotensin receptor blocker and neprilysin inhibitor (ARNI) remains low, and many patients are unable to tolerate the medication due to hypotension at the currently recommended starting dose. HYPOTHESIS: The aim of this study is to assess if lower than standard doses of ARNI, sacubitril/valsartan (S/V), significantly reduces NT-proBNP and leads to any change in diuretic dose, serum potassium, or creatinine. METHODS: In a retrospective study of 278 patients who were started on a low dose S/V at a single medical center, 45 patients were selected for the study cohort. Patients were subcategorized to Group 1 (n = 10): very low dose S/V (half a tab of 24/26 mg BID), Group 2 (n = 10): very low dose titrated to low dose S/V, and Group 3 (n = 25): low dose S/V (24/26 mg BID). NT-proBNP, diuretic dose, serum potassium, and creatinine were compared before and after initiation of S/V. RESULTS: Among all groups, there was a significant reduction in NT-proBNP level (Group 1: p < .01, Group 2: p < .01, and Group 3: p < .001). In addition, there was a significant reduction in diuretic dose across all groups combined (furosemide 53 mg/day vs. 73 mg/day; p = .03), with 17.8% (8/45) patients being able to discontinue their diuretic completely. There was no significant change in potassium or creatinine. CONCLUSIONS: Lower than standard dose of S/V significantly reduces NT-proBNP and diuretic requirement without change in potassium or creatinine, which provides hope that patients who cannot tolerate standard doses of S/V due to hypotension may be able to receive the benefits of S/V therapy.
BACKGROUND: Widespread use of angiotensin receptor blocker and neprilysin inhibitor (ARNI) remains low, and many patients are unable to tolerate the medication due to hypotension at the currently recommended starting dose. HYPOTHESIS: The aim of this study is to assess if lower than standard doses of ARNI, sacubitril/valsartan (S/V), significantly reduces NT-proBNP and leads to any change in diuretic dose, serum potassium, or creatinine. METHODS: In a retrospective study of 278 patients who were started on a low dose S/V at a single medical center, 45 patients were selected for the study cohort. Patients were subcategorized to Group 1 (n = 10): very low dose S/V (half a tab of 24/26 mg BID), Group 2 (n = 10): very low dose titrated to low dose S/V, and Group 3 (n = 25): low dose S/V (24/26 mg BID). NT-proBNP, diuretic dose, serum potassium, and creatinine were compared before and after initiation of S/V. RESULTS: Among all groups, there was a significant reduction in NT-proBNP level (Group 1: p < .01, Group 2: p < .01, and Group 3: p < .001). In addition, there was a significant reduction in diuretic dose across all groups combined (furosemide 53 mg/day vs. 73 mg/day; p = .03), with 17.8% (8/45) patients being able to discontinue their diuretic completely. There was no significant change in potassium or creatinine. CONCLUSIONS: Lower than standard dose of S/V significantly reduces NT-proBNP and diuretic requirement without change in potassium or creatinine, which provides hope that patients who cannot tolerate standard doses of S/V due to hypotension may be able to receive the benefits of S/V therapy.
Authors: Kevin S Shah; Haolin Xu; Roland A Matsouaka; Deepak L Bhatt; Paul A Heidenreich; Adrian F Hernandez; Adam D Devore; Clyde W Yancy; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2017-11-12 Impact factor: 24.094
Authors: Stephen J Greene; Javed Butler; Nancy M Albert; Adam D DeVore; Puza P Sharma; Carol I Duffy; C Larry Hill; Kevin McCague; Xiaojuan Mi; J Herbert Patterson; John A Spertus; Laine Thomas; Fredonia B Williams; Adrian F Hernandez; Gregg C Fonarow Journal: J Am Coll Cardiol Date: 2018-07-24 Impact factor: 24.094
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: N Engl J Med Date: 2014-08-30 Impact factor: 91.245
Authors: Nicholas Y Tan; Lindsey R Sangaralingham; S Jeson Sangaralingham; Xiaoxi Yao; Nilay D Shah; Shannon M Dunlay Journal: JACC Heart Fail Date: 2019-12-11 Impact factor: 12.035
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: John J V McMurray; Milton Packer; Akshay S Desai; Jim Gong; Martin P Lefkowitz; Adel R Rizkala; Jean Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile Journal: Eur J Heart Fail Date: 2013-04-05 Impact factor: 15.534
Authors: Orly Vardeny; Brian Claggett; Milton Packer; Michael R Zile; Jean Rouleau; Karl Swedberg; John R Teerlink; Akshay S Desai; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon Journal: Eur J Heart Fail Date: 2016-06-10 Impact factor: 15.534
Authors: Amitabh C Pandey; Derek Jer; Ruth S Kuo; David H Yoo; Antonio Christophy; Rajeev C Mohan; Ajay V Srivastava; James Thomas Heywood Journal: Clin Cardiol Date: 2020-12-05 Impact factor: 2.882